IsoPlexis’ Immune Monitoring Helps Identify Early Factors of Long COVID in Cell Publication
February 10 2022 - 7:00AM
IsoPlexis Corporation (NASDAQ: ISO), the Superhuman Cell
Company, today announced the publication of a study in Cell,
led by the Institute for Systems Biology and Seattle COVID
consortium, in which researchers used IsoPlexis’ single-cell
functional proteomics platform to identify factors that may predict
sustained disease after COVID-19 infection, also known as
Post-Acute Sequelae of COVID-19 (PASC) or Long COVID.
In the paper, titled "Multiple Early Factors Anticipate
Post-Acute COVID-19 Sequelae," researchers correlated patient
symptoms with in-depth profiling of blood cells and plasma
components throughout COVID-19 infection to identify factors
associated with the development of PASC. PASC is the technical term
for Long COVID, i.e., a range of new, returning, or ongoing health
problems people can experience four or more weeks following
infection. Authors followed 309 patients from initial clinical
diagnosis to early-stage recovery from acute disease, spanning up
to 2-3 months post diagnosis, as well as 457 control patients.
Using IsoPlexis’ single-cell functional proteomics platform, the
researchers were able to identify correlations between the enhanced
presence of certain polyfunctional immune cell types and the
presentation of inflammation associated with PASC:
- Increased frequency of “supervillain” T cell subsets (CD4+ and
CD8+ T cells) is positively associated with certain PASC
symptoms/conditions, or endotypes, and disease severity at
convalescence.
- Similarly, presence of “supervillain” monocytes in convalescent
patients compared to healthy subjects is correlated with all of the
major PASC endotypes, indicating the impact of monocytes on a
sustained inflammation at convalescence.
- Natural killer (NK) cells in PASC
endotypes played less of an active role in convalescence
inflammation of PASC.
IsoPlexis’ single-cell functional proteomics provided a unique
assessment to dissect the functional impacts of different cell
types across multiple timepoints and the interplay between innate
and adaptive immune responses that contributed to effector
functions or inflammation in PASC.
This study follows a previously published Cell paper titled
“Longitudinal profiling of respiratory and systemic immune
responses reveals myeloid cell-driven lung inflammation in severe
COVID-19,” where IsoPlexis’ platform identified mechanisms of
inflammation in moderate to severe cases of COVID-19.
"Understanding the predictive biomarkers that correlate with the
development of Long COVID, or PASC, is essential to identifying
sustained inflammation early and may be key to the development of
preventative measures and treatments for PASC and other chronic
illnesses. This study shows how researchers can leverage single
cell functional proteomics to gain a better understanding of how
single-cell polyfunctionality of various immune cell types affect
post-COVID-19 patient outcomes,” said James R. Heath, Ph.D. Dr.
Heath is President and Professor at the Institute for Systems
Biology in Seattle, and a Professor of Bioengineering at the
University of Washington. He also co-founded IsoPlexis and is a
member of the IsoPlexis scientific advisory board.
Visit our publications page to see the wide range of
use cases for single-cell proteomics in accelerating a variety of
immune therapies in high impact publications.
About IsoPlexis
IsoPlexis is the Superhuman Cell company.
IsoPlexis’ systems uniquely identify a comprehensive range of
multifunctional single cells, i.e. the superhero cells in the human
body. These cells enable researchers to understand and predict
disease progression, treatment resistance and therapeutic efficacy
to advance all of human health.
IsoPlexis has been named Top Innovation or Design by The
Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple
others. The IsoPlexis platform is used globally by researchers,
including those at the top 15 global pharmaceutical companies and
at two-thirds of leading U.S. comprehensive cancer centers.
Cautionary Note Regarding Forward Looking
Statements
Certain statements in this press release are forward-looking
statements that are subject to risks and uncertainties that could
cause results to be materially different than expectations. Forward
looking statements may be identified, in part, by use of words such
as “is” or “may”. Important factors that could cause actual results
to differ materially include: the rate of adoption of the Company's
technology by its customers and potential customers as well as the
risk factors set forth in the Risk Factors section of the Company's
prospectus filed with the SEC. These forward-looking statements are
not guarantees of future performance and speak only as of the date
hereof, and, except as required by law, IsoPlexis disclaims any
obligation to update these forward-looking statements to reflect
future events or circumstances.
Investor Contactinvestors@isoplexis.com
Press Contactpress@isoplexis.com
Related Linkswww.isoplexis.com
SOURCE IsoPlexis
Related Links
www.isoplexis.com
IsoPlexis (NASDAQ:ISO)
Historical Stock Chart
From Jun 2024 to Jul 2024
IsoPlexis (NASDAQ:ISO)
Historical Stock Chart
From Jul 2023 to Jul 2024